Larotrectinib Sulfate and Prochlorperazine Edisylate

• Generic Name: larotrectinib
• Dosage Forms: n.a.
• Other Brand Names: Vitrakvi

Treatment of solid tumors harboring an NTRK fusion (without a known acquired mutation for resistance) in patients who have metastatic disease or may experience severe morbidity following surgical resection and whose disease progressed following prior therapy or those who are not candidates for other treatment options (designated an orphan drug by FDA for these cancers).

Accelerated approval based on overall response rate and duration of response. Continued approval may be contingent on verification and description of clinical benefit in confirmatory studies.

Confirmation of the presence of NTRK fusion is necessary prior to initiation of therapy. In clinical studies, NTRK fusion status of tumor specimens was determined by fluorescence in situ hybridization (FISH), reverse transcription-polymerase chain reaction (RT-PCR), or next-generation sequencing (NGS).

• Generic Name: prochlorperazine
• Dosage Forms: n.a.
• Other Brand Names: Compazine, Compro

Symptomatic management of psychotic disorders (i.e., schizophrenia).

Short-term management of nonpsychotic anxiety.

Efficacy established in patients with generalized anxiety disorder; not established whether prochlorperazine is useful for the management of other nonpsychotic conditions in which anxiety or manifestations that mimic anxiety are evident (e.g., physical illness, organic mental conditions, agitated depression, character pathologies).

Because of the risks of toxicity, use only as an alternative to other less toxic anxiolytic agents (e.g., benzodiazepines) in most patients.

Management of severe nausea and vomiting of various etiologies (e.g., postoperative, acute migraine, toxins, radiation, or cytotoxic drugs).

Not effective in preventing vertigo or motion sickness, or for the management of emesis caused by the action of drugs on the nodose ganglion or locally on the GI tract.

Use not recommended for the prevention and treatment of nausea and vomiting associated with pregnancy except in cases of severe nausea and vomiting so serious and intractable that pharmacologic intervention is required and the potential benefits justify the possible risks to the fetus. (See Fetal/Neonatal Morbidity under Cautions.)

Has not been shown to be effective for the management of behavioral complications in patients with mental retardation.